The effect of CDK4 inhibitor to AML

被引：0
|
作者：
wang, Jie [1 ]
机构：
[1] Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [21] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
    Sorrentino, J.
    Bisi, J.
    Thompson, D.
    Lai, A.
    Strum, J.
    Roberts, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E48
  • [23] CDK4/6 inhibitor-related cardiovascular disorders
    Reactions Weekly, 2025, 2042 (1) : 8 - 8
  • [24] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [25] FDA approves Novartis's CDK4/6 inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (04) : 229 - 229
  • [26] Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
    van Aken, Evert S. M.
    Beeker, Aart
    Houtenbos, Ilse
    Pos, Floris J.
    Linn, Sabine C.
    Elkhuizen, Paula H. M.
    de Jong, Monique C.
    CANCER REPORTS, 2022, 5 (02)
  • [27] CDK4/6 inhibitor-related safety signals
    Reactions Weekly, 2024, 2028 (1) : 6 - 6
  • [28] Cdk4/6 kinase inhibitor resistance in prostate cancer
    De Leeuw, Renee
    Schiewer, Matthew J.
    McNair, Christopher
    Augello, Michael A.
    Yoshida, Akihiro
    Hazard, Edward S.
    Courtney, Sean
    Hardiman, Gerard T.
    Drake, Justin
    Feng, Felix Y.
    Tomlins, Scott
    Hussain, Maha H.
    Diehl, J. Alan
    Kelly, William K.
    Knudsen, Karen E.
    CANCER RESEARCH, 2017, 77
  • [29] CDK4/6 inhibitor synergizes with mTOR inhibitor to suppress cholangiocarcinoma pathogenesis
    Song, Xinhua
    Liu, Xianqiong
    Wang, Jingxiao
    Chen, Xin
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [30] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
12345